Skip to content
TrialScanner

NCT03328026

Combination Study of SV-BR-1-GM With Retifanlimab

Phase 1/Phase 2CompletedBCTXLead

Registry record

Lead sponsor
BriaCell Therapeutics Corporation
Conditions
Breast Cancer; Breast Neoplasm; Metastatic Breast Cancer; Breast Cancer Metastatic
Primary completion
Mar 24, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03328026 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03328026: Combination Study of... | TrialScanner